PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SciClone Pharmaceuticals (6600.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG4271B1023
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Highlights

Market CapHK$11.70B
PE Ratio9.82
Total Revenue (TTM)HK$1.60B
Gross Profit (TTM)HK$1.19B
Year RangeHK$8.75 - HK$18.66
Target PriceHK$17.94

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


SciClone Pharmaceuticals

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in SciClone Pharmaceuticals, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%2024FebruaryMarchAprilMayJune
41.17%
15.24%
6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

S&P 500

Returns By Period

SciClone Pharmaceuticals had a return of 34.48% year-to-date (YTD) and 68.65% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date34.48%14.75%
1 month2.18%2.85%
6 months41.18%15.30%
1 year68.65%25.37%
5 years (annualized)N/A13.19%
10 years (annualized)N/A10.82%

Monthly Returns

The table below presents the monthly returns of 6600.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-20.26%17.30%23.20%11.85%3.12%34.48%
202314.35%4.11%3.75%15.82%-11.47%4.35%2.66%-12.57%5.60%3.10%32.04%2.35%74.55%
2022-2.89%-6.55%3.57%1.97%-0.23%9.71%-10.80%-7.99%-13.31%-7.27%9.93%31.38%-0.05%
2021-17.23%1.41%-6.72%1.22%-23.36%-14.97%7.11%1.73%-14.27%-4.63%-53.99%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of 6600.HK is 90, placing it in the top 10% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of 6600.HK is 9090
6600.HK (SciClone Pharmaceuticals)
The Sharpe Ratio Rank of 6600.HK is 9393Sharpe Ratio Rank
The Sortino Ratio Rank of 6600.HK is 9090Sortino Ratio Rank
The Omega Ratio Rank of 6600.HK is 9090Omega Ratio Rank
The Calmar Ratio Rank of 6600.HK is 9090Calmar Ratio Rank
The Martin Ratio Rank of 6600.HK is 8888Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for SciClone Pharmaceuticals (6600.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


6600.HK
Sharpe ratio
The chart of Sharpe ratio for 6600.HK, currently valued at 2.00, compared to the broader market-2.00-1.000.001.002.003.002.00
Sortino ratio
The chart of Sortino ratio for 6600.HK, currently valued at 2.72, compared to the broader market-4.00-2.000.002.004.006.002.72
Omega ratio
The chart of Omega ratio for 6600.HK, currently valued at 1.38, compared to the broader market0.501.001.502.001.38
Calmar ratio
The chart of Calmar ratio for 6600.HK, currently valued at 1.69, compared to the broader market0.002.004.006.001.69
Martin ratio
The chart of Martin ratio for 6600.HK, currently valued at 7.31, compared to the broader market0.0010.0020.007.31
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.19, compared to the broader market-2.00-1.000.001.002.003.002.19
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.10, compared to the broader market-4.00-2.000.002.004.006.003.10
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.75, compared to the broader market0.002.004.006.001.75
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.21, compared to the broader market0.0010.0020.008.21

Sharpe Ratio

The current SciClone Pharmaceuticals Sharpe ratio is 2.00. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of SciClone Pharmaceuticals with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.501.001.502.002.503.002024FebruaryMarchAprilMayJune
2.00
2.17
6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Dividends

Dividend History

SciClone Pharmaceuticals granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.00 per share.


PeriodTTM20232022
DividendHK$0.00HK$0.39HK$0.35

Dividend yield

0.00%2.80%4.22%

Monthly Dividends

The table displays the monthly dividend distributions for SciClone Pharmaceuticals. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.39HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.39
2022HK$0.35HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.35

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-40.00%-30.00%-20.00%-10.00%0.00%2024FebruaryMarchAprilMayJune0
-0.29%
6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the SciClone Pharmaceuticals. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SciClone Pharmaceuticals was 68.49%, occurring on Oct 28, 2022. Recovery took 349 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.49%Mar 4, 2021409Oct 28, 2022349Apr 2, 2024758
-0.65%May 28, 20242May 29, 20242May 31, 20244
-0.64%Jun 11, 20242Jun 12, 20246Jun 20, 20248
-0.55%Apr 16, 202411Apr 30, 20242May 3, 202413
-0.45%Apr 8, 20242Apr 9, 20243Apr 12, 20245

Volatility

Volatility Chart

The current SciClone Pharmaceuticals volatility is 1.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%2024FebruaryMarchAprilMayJune
1.62%
2.33%
6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of SciClone Pharmaceuticals over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items